Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Upstream Bio Inc. (NASDAQ:UPB) shares are trading lower during Friday’s session as the stock reacts to recent developments in its clinical trials.Over the last few days, the stock has plunged more than 54%.The decline follows a report highlighting the company’s results for its asthma treatment.VALIANT Trial Shows 56% Reduction in Asthma AttacksThe VALIANT trial demonstrated statistically significant reductions in the annualized asthma exacerbation rate (AAER) of 56% for the 100 mg every 12 weeks dosing comp ...